CN109069548A - 肝内胆汁淤积及相关肝疾病的治疗 - Google Patents

肝内胆汁淤积及相关肝疾病的治疗 Download PDF

Info

Publication number
CN109069548A
CN109069548A CN201680073160.6A CN201680073160A CN109069548A CN 109069548 A CN109069548 A CN 109069548A CN 201680073160 A CN201680073160 A CN 201680073160A CN 109069548 A CN109069548 A CN 109069548A
Authority
CN
China
Prior art keywords
composition
bacterial strain
atcc
activity
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680073160.6A
Other languages
English (en)
Chinese (zh)
Inventor
F.卡勒森
B.莫尔斯达姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabogen AB
Original Assignee
Metabogen AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabogen AB filed Critical Metabogen AB
Publication of CN109069548A publication Critical patent/CN109069548A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680073160.6A 2015-12-14 2016-12-14 肝内胆汁淤积及相关肝疾病的治疗 Pending CN109069548A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562266771P 2015-12-14 2015-12-14
US62/266771 2015-12-14
PCT/EP2016/080941 WO2017102816A1 (en) 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases

Publications (1)

Publication Number Publication Date
CN109069548A true CN109069548A (zh) 2018-12-21

Family

ID=57570064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073160.6A Pending CN109069548A (zh) 2015-12-14 2016-12-14 肝内胆汁淤积及相关肝疾病的治疗

Country Status (16)

Country Link
US (1) US20180369297A1 (https=)
EP (1) EP3389680B1 (https=)
JP (2) JP2018537484A (https=)
KR (1) KR20180094950A (https=)
CN (1) CN109069548A (https=)
AU (1) AU2016374365B2 (https=)
BR (1) BR112018012022A2 (https=)
CA (1) CA3008195A1 (https=)
CL (1) CL2018001548A1 (https=)
ES (1) ES2962302T3 (https=)
IL (1) IL259480B2 (https=)
MX (1) MX2018007227A (https=)
RU (1) RU2743405C2 (https=)
SG (1) SG11201804255QA (https=)
WO (1) WO2017102816A1 (https=)
ZA (1) ZA201804660B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
CN112280720B (zh) * 2020-11-19 2021-07-13 山东龙昌动物保健品有限公司 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用
US20240122996A1 (en) * 2021-02-08 2024-04-18 Liscure Biosciences Co., Ltd. Pharmaceutical composition for preventing or treating cholestatic liver injury comprising leuconostoc citreum strain as active ingredient
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
GB2628547A (en) * 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102539791A (zh) * 2012-01-09 2012-07-04 宁波天康生物科技有限公司 总胆汁酸的定量测定及测定试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
AU4905300A (en) * 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ES2381211T3 (es) * 2006-02-15 2012-05-24 Nestec S.A. Uso del Bifidobacterium longum para prevenir y tratar inflamaciones
US20120128633A1 (en) * 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
CA2926466C (en) * 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102539791A (zh) * 2012-01-09 2012-07-04 宁波天康生物科技有限公司 总胆汁酸的定量测定及测定试剂盒

Also Published As

Publication number Publication date
RU2018124487A3 (https=) 2020-05-29
KR20180094950A (ko) 2018-08-24
CL2018001548A1 (es) 2018-07-20
RU2743405C2 (ru) 2021-02-18
MX2018007227A (es) 2018-08-01
ES2962302T3 (es) 2024-03-18
JP2018537484A (ja) 2018-12-20
BR112018012022A2 (pt) 2018-12-04
IL259480A (en) 2018-07-31
JP2022166039A (ja) 2022-11-01
WO2017102816A1 (en) 2017-06-22
US20180369297A1 (en) 2018-12-27
RU2018124487A (ru) 2020-01-10
IL259480B1 (en) 2023-05-01
SG11201804255QA (en) 2018-06-28
AU2016374365B2 (en) 2023-04-13
AU2016374365A1 (en) 2018-07-12
IL259480B2 (en) 2023-09-01
CA3008195A1 (en) 2017-06-22
ZA201804660B (en) 2022-12-21
EP3389680C0 (en) 2023-10-11
EP3389680A1 (en) 2018-10-24
EP3389680B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
CN109069548A (zh) 肝内胆汁淤积及相关肝疾病的治疗
Ahmadi et al. The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial
US11026955B2 (en) Synthetic bile acid compositions and methods
US9987291B2 (en) Synthetic bile acid compositions and methods
BR112020002992A2 (pt) composições e métodos para tratamento de doença colestática
WO2008077614A2 (de) Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden
DK2266619T3 (en) PHARMACEUTICAL PREPARATION BASED ON A LIVING PROTECTIVE AGENT AND A PREBIOTIC AGENT, PREPARATION AND USE OF IT
JP4057091B2 (ja) 細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用
Xiao et al. Phytosterols protect against osteoporosis by regulating gut microbiota
Zhang et al. Microbial bile acid metabolite ameliorates mycophenolate mofetil-induced gastrointestinal toxicity through vitamin D3 receptor
Miettinen et al. Origins of fecal neutral steroids in rats
Reddy et al. Antilithogenic and hypocholesterolemic effect of dietary fenugreek seeds (Trigonella foenum-graecum) in experimental mice
RU2310463C1 (ru) Гепатопротекторный пробиотик
US20240041821A1 (en) 1,8-cineole containing composition for therapeutic use
RU2400235C1 (ru) Способ лечения больных с дисбактериозом кишечника
Plotnikoff Elevated deoxycholic acid and idiopathic recurrent acute pancreatitis: A case report with 48 months of follow-up
Chen et al. Contribute to Ageing and Ageing-Related Diseases
Hanafi et al. Bile Acid Signaling and Cardioprotection
US20170071968A1 (en) Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating
Yoshinari Influences of food ingredients on enterohepatic circulation of bile acids
Kobyliak et al. ARE THE TYPE OF PROBIOTIC STRAINS AND THEIR AMOUNT EQUALLY EFFECTIVE FOR NAFLD PREVENTION: EXPERIMENTAL COMPARATIVE STUDY?
Macfarlane et al. Human Colonic Microbes: Ecology, Physiology and Metabolic Potential of Intestinal Bacteria
Wang Hypocholesterolemic Activity of Cholesterol and Phytosterol Derivatives in Hamsters
JP2015193592A (ja) シクロアルテノール含有組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002061

Country of ref document: HK